Relapsing-remitting Multiple Sclerosis
📧 Sign up to get email alerts when something new happens for Relapsing-remitting Multiple Sclerosis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2009-01-05Clinical Trial Update: Eszopiclone for Improving Sleep in Multiple Sclerosis (MS) [NA]
Clinical trial update shows completion of a study evaluating eszopiclone for improving sleep in patients with Relapsing Remitting Multiple S…
-
CLINICAL_TRIALS trial_result · 2008-12-19Clinical Trial Update: BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients [Phase 3]
Phase 3 trial update reporting outcomes of a new dose of Betaferon/Betaseron (interferon beta-1b) in relapsing-remitting multiple sclerosis.…
-
CLINICAL_TRIALS trial_result · 2008-09-04Clinical Trial Update: How Side Effects of Avonex Are Affected by Gradually Increasing to Full Dose vs Starting at Full Dose [Phase 4]
A Phase 4 trial comparing gradual dose escalation of Avonex versus starting at full dose to influence side effects in relapsing-remitting mu…
-
CLINICAL_TRIALS trial_result · 2008-08-05Clinical Trial Update: Study of Subcutaneous Daclizumab in Patients With Active, Relapsing Forms of Multiple Sclerosis [Phase 2]
This clinical trial update reports the completion of a Phase 2 study evaluating subcutaneous daclizumab in patients with active, relapsing f…
-
CLINICAL_TRIALS trial_result · 2008-05-09Clinical Trial Update: AVONEX® Combination Trial - "ACT" [Phase 4]
Completed Phase 4 AVONEX combination trial (ACT) in relapsing-remitting multiple sclerosis.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2008-02-11Clinical Trial Update: BHT-3009 Immunotherapy in Relapsing Remitting Multiple Sclerosis [Phase 2]
A Phase 2 trial evaluating BHT-3009 immunotherapy for relapsing-remitting multiple sclerosis has completed.
-
CLINICAL_TRIALS trial_result · 2008-01-30Clinical Trial Update: Investigating if Interferon-Beta Can be Used in Patients With MS After They Have Developed Neutralizing Antibodies [Phase 4]
A Phase 4 clinical trial completed evaluating whether interferon-beta can be used in patients with relapsing-remitting multiple sclerosis af…
-
CLINICAL_TRIALS trial_result · 2007-12-13Clinical Trial Update: Does Quality of Life Improve in Multiple Sclerosis Patients Treated With Interferon Beta-1a? [Phase 4]
Phase 4 clinical trial update assessing whether Interferon Beta-1a improves quality of life in patients with relapsing-remitting multiple sc…
-
CLINICAL_TRIALS trial_result · 2007-12-05Clinical Trial Update: An fMRI Study of Treatment Optimization Comparing Two Disease Modifying Therapies Used to Treat Relapsing Remitting Multiple Sclerosis
An fMRI study comparing two disease-modifying therapies for relapsing-remitting multiple sclerosis was terminated. The trial assessed treatm…
-
CLINICAL_TRIALS research · 2007-10-16Clinical Trial Update: A fMRI(Functional Magnetic Resonance Imaging) Research Study to Learn More About Multiple Sclerosis and Individuals Potentially Experiencing Memory Difficulties [Phase 4]
A Phase 4 completed clinical trial update describing an fMRI study to better understand Relapsing-Remitting Multiple Sclerosis and memory di…
-
CLINICAL_TRIALS trial_result · 2007-01-05Clinical Trial Update: Evaluation of Efficiency of Ritalin in Multiple Sclerosis (MS) Patients [Phase 1]
Phase 1 clinical trial update evaluating the effectiveness of Ritalin (methylphenidate) in patients with relapsing-remitting and primary pro…
-
CLINICAL_TRIALS research · 2006-09-07Clinical Trial Update: Combination Therapy (Provigil + Avonex) to Treat Cognitive Problems in MS [NA]
Clinical trial update evaluating a combination of modafinil (Provigil) and interferon beta-1a (Avonex) to treat cognitive problems in Relaps…
-
CLINICAL_TRIALS trial_result · 2006-08-07Clinical Trial Update: Omega-3 Fatty Acid Treatment in Multiple Sclerosis [Phase 2, Phase 3]
A clinical trial evaluating omega-3 fatty acid treatment for relapsing-remitting multiple sclerosis has completed its Phase 2 and Phase 3 st…